FIELD: medicine.
SUBSTANCE: patients are supposed to take agents containing organic lithium salts specified in a group: aspartate, acetate, glycinate, gluconate, lactate, nicotinate, adipate, citrate, salicylate, orotate, benzoate, pyroglutamate, tyrosinate, argininate, pyruvate, lysinate, malate, alaninate, lactate, cysteinate, tryptophanate. A daily dose equivalent to elementary lithium makes 50-1000 mg.
EFFECT: invention provides effective compensation of lithium deficiency and a possibility of long-term dementia prevention with no need for patient's blood lithium control that is ensured by small doses of the administered medicinal preparations.
5 cl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR PREVENTING AND TREATING NEURODEGENERATIVE PATHOLOGY AND VASCULAR DEMENTIA (VERSIONS) | 2014 |
|
RU2582962C1 |
| LITHIUM-CONTAINING AGENT TO PREVENT AND TREAT CEREBROVASCULAR DISEASES AND METHOD OF APPLICATION THEREOF | 2008 |
|
RU2367427C1 |
| NEUROPROTECTIVE AGENT | 2016 |
|
RU2614697C1 |
| METHOD FOR PREPARING LITHIUM SALT OF COMENIC ACID AND USING IT AS ANTIOXIDANT, STRESS- AND NEUROPROTECTIVE AGENT | 2011 |
|
RU2477722C1 |
| SYNTHETIC TETRAPEPTIDE HAEE AND DERIVATIVES THEREOF INTENDED FOR PROTECTION OF HUMAN NEURON FUNCTION | 2023 |
|
RU2822602C1 |
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2450000C2 |
| POLYVITAMIN KIT FOR WOMEN | 2010 |
|
RU2443422C2 |
| SYGETHIN-BASED PHARMACEUTICAL STRUCTURE FOR OSTEOPOROSIS PREVENTION AND TREATMENT (VERSIONS) | 2007 |
|
RU2356546C1 |
| CITRIC SALT OF INDOLE DERIVATIVE, METHOD FOR PRODUCING THEREOF, ADMINISTERING THEREOF AND BASED PHARMACEUTICAL COMPOSITION | 2007 |
|
RU2415137C2 |
| DIAGNOSTIC TECHNIQUE FOR REDUCED POTASSIUM LEVEL IN ERYTHROCYTES | 2015 |
|
RU2593982C1 |
